America in Transition Pages

Monday, April 11, 2016

FDA Approves AbbVie's BCL-2 Targeting Drug for CLL

(MedPage Today) -- Venclexta achieved objective response rate of 80% in disease with 17-p deletion

from MedPage Today Washington Watch http://ift.tt/1Nl2Xlh
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)